OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma
NCT: NCT07751796 · NOT_YET_RECRUITING
Brief Summary
Upper tract urothelial carcinoma (UTUC) is difficult to stage accurately because cross-sectional imaging and ureteroscopic biopsy may not reliably demonstrate muscular or periureteral invasion. This exploratory study evaluates whether a 60-MHz OptiCross HD intravascular ultrasound (IVUS) catheter can be safely introduced into the renal pelvis or ureter during planned surgery and provide intraluminal images that correspond to the final pathologic T stage. Fifteen adults with suspected or confirmed UTUC who are already scheduled for radical nephroureterectomy (RNU) will undergo one IVUS examination immediately before surgery. The IVUS result will not alter the planned treatment. Three independent reviewers who are blinded to clinical and pathologic information will assess invasion depth and image quality. IVUS-based T stage will be compared with postoperative pathology. Technical success, visualization of ureteral wall layers and lesion boundaries, and adverse events will also be evaluated through 3 months after surgery.
Frequently Asked Questions
What is OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma?
OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma is a clinical trial registered under NCT07751796. Current status: NOT_YET_RECRUITING.
What is the status of NCT07751796?
The current status of NCT07751796 (OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma) is: NOT_YET_RECRUITING.
When did OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma start?
OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma started on 2026-09-01.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.